Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab Adherence in Hidradenitis Suppurativa
NCT04132388Phase 4Withdrawn
- Sponsor
- Wake Forest University Health Sciences
- Start
- Aug 2020
- Primary completion
- Sep 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of adalimumab in hidradenitis suppurativa (HS) (2 arms), sponsored by Wake Forest University Health Sciences. Primary endpoints: Number of days between each dose at 26 weeks and Percentage of patients who achieve adherence success at 26 weeks. Planned start Aug 2020; status: withdrawn.
02
Drugs
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT04132388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04132388.